KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.98

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.

Myung-Ju Ahn, Aaron Lisberg, Yasushi Goto, Jacob Sands, Min Hee Hong, Luis Paz-Ares, Elvire Pons-Tostivint, Maurice Pérol, Enriqueta Felip, Shunichi Sugawara, Hidetoshi Hayashi, Byoung Chul Cho, George Blumenschein, Elaine Shum, Jong-Seok Lee, Rebecca S Heist, Robin Cornelissen, Wen-Cheng Chang, Dariusz Kowalski, Hong Zebger-Gong, Michael Chargualaf, Wen Gu, Lan Lan, Paul Howarth, Richard Joseph, Isamu Okamoto

J Thorac Oncol 20(11) 1669-1682

PMID40516821
PMCID-
DOI10.1016/j.jtho.2025.06.002
发表日期2025-06-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:This is a pooled analysis of a phase II and a phase III trial; it is not a single Phase III RCT itself. The analysis combines results from multiple studies, including a non-randomized phase II component.
摘要

摘要

BACKGROUND: This exploratory analysis assessed datopotamab deruxtecan (Dato-DXd) in pretreated patients with advanced or metastatic NSCLC and EGFR mutations. METHODS: Data were pooled from the phase II TROPION-Lung05 (NCT04484142) and phase III TROPION-Lung01 (NCT04656652) trials. Patients with EGFR-mutated advanced or metastatic NSCLC, who had received previous targeted therapies and platinum-based chemotherapy, received Dato-DXd 6 mg/kg (TROPION-Lung05) or were randomized to Dato-DXd 6 mg/kg or docetaxel 75 mg/m2 (TROPION-Lung01) once every 3 weeks. End points included objective response rate, duration of response, and progression-free survival, all per blinded independent central review, overall survival, and safety. RESULTS: In total, 117 patients with EGFR mutations who received Dato-DXd were included in the pool. The population was heavily pretreated (median three lines of previous therapies; range, 1-5) and predominantly Asian (69%). The most common mutations were exon 19 deletion (51%), L858R (32%), and T790M (27%); more than one EGFR mutation could be present. The confirmed objective response rate was 43% (95% confidence interval [CI]: 34-52), including five complete responses (4%). Median duration of response was 7.0 months (95% CI: 4.2-9.8). Median progression-free survival and overall survival were 5.8 (95% CI: 5.4-8.2) and 15.6 months (95% CI: 13.1-19.0), respectively. The safety profile of Dato-DXd was consistent with the individual studies. No new safety signals were observed. Rates of grade greater than or equal to 3 treatment-related adverse events and serious adverse events were 23% and 6%, respectively. CONCLUSION: Dato-DXd demonstrated meaningful clinical activity in patients with EGFR-mutated advanced or metastatic NSCLC who had progressed on EGFR-directed therapies and chemotherapy, with an acceptable safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。